Immix Biopharma, Inc. (IMMX) Bundle
A Brief History of Immix Biopharma, Inc. (IMMX)
Company Formation and Early Developments
Immix Biopharma, Inc., founded in 2020, is a biopharmaceutical company focused on developing advanced therapies for cancer and related diseases. The company’s headquarters are located in Los Angeles, California. Since its inception, Immix Biopharma has aimed to innovate drug development processes, particularly in the area of immune-oncology.
Initial Public Offering (IPO)
On March 5, 2021, Immix Biopharma went public via an IPO. The company offered 1.5 million shares at a price of $5.00 per share. This initial offering raised approximately $7.5 million in gross proceeds.
Key Therapeutic Development
Immix Biopharma's lead product candidate, IMX-140, focuses on treating various types of cancer. As of October 2023, the drug is in the clinical trial phase, showcasing promising results in Phase 1 studies, particularly in reducing tumor size in patients with solid tumors. The company reported that over 80% of trial participants showed preliminary signs of tumor reduction.
Financial Performance
As of Q3 2023, Immix Biopharma reported revenue of $2.3 million from collaborative agreements and research grants. The company’s research and development expenses for the same period totaled $5.1 million, reflecting an increase in clinical trial expenditures.
Stock Performance Overview
Since its IPO, IMMX's stock has experienced fluctuations. As of October 2023, the stock price was approximately $3.20, a decrease of around 36% from its IPO price. The market capitalization stood at approximately $50 million.
| Year | Revenue ($ million) | R&D Expenses ($ million) | Stock Price ($) |
|---|---|---|---|
| 2021 | 1.1 | 4.0 | 5.00 |
| 2022 | 1.8 | 5.0 | 4.50 |
| 2023 (Q3) | 2.3 | 5.1 | 3.20 |
Partnerships and Collaborations
Immix Biopharma has entered into several partnerships with academic institutions and research organizations to bolster its drug development capabilities. Notable collaborations include agreements with UCLA and Stanford University for ongoing research in immune-oncology.
Future Outlook
Looking forward, Immix Biopharma plans to expand its pipeline by initiating new clinical trials for IMX-140 and potential new candidates. The company aims to secure additional funding, targeting an increase of $15 million through future financing rounds to support its development program.
Market Position and Competitors
As of 2023, Immix Biopharma operates in a competitive landscape alongside companies like Moderna and Novartis. The immune-oncology market is estimated to reach $100 billion by 2026, offering significant opportunities for growth.
A Who Owns Immix Biopharma, Inc. (IMMX)
Company Overview
Immix Biopharma, Inc. (IMMX) is a publicly traded biopharmaceutical company focused on developing innovative therapies for cancer and other serious diseases. The company is engaged in the research and development of treatments that leverage proprietary therapeutic platforms.
Ownership Structure
The ownership of Immix Biopharma, Inc. is composed of institutional investors, individual shareholders, and company insiders. The following table summarizes the major shareholders and their respective ownership percentages as of the most recent financial filings.
| Shareholder Type | Name | Ownership Percentage | Number of Shares Owned |
|---|---|---|---|
| Institutional Investor | The Vanguard Group, Inc. | 7.5% | 1,200,000 |
| Institutional Investor | BlackRock, Inc. | 6.9% | 1,100,000 |
| Insider | Peter L. de Figueiredo (CEO) | 5.0% | 800,000 |
| Insider | Mark A. Mitchell (CFO) | 3.5% | 560,000 |
| Individual Shareholder | Various Individual Investors | 77.1% | 12,300,000 |
Recent Stock Performance
As of October 2023, the stock price for Immix Biopharma, Inc. is approximately $5.25 per share. The company has experienced fluctuations in its stock price over the year, influenced by clinical trial results and market conditions.
Market Capitalization
The market capitalization of Immix Biopharma, Inc. is approximately $85 million, reflecting its position in the biopharmaceutical sector.
Recent Financial Performance
For the Q2 2023 financial report, Immix Biopharma, Inc. reported the following:
| Metric | Amount (USD) |
|---|---|
| Revenue | $1.5 million |
| Net Loss | ($3.2 million) |
| Cash and Cash Equivalents | $10.5 million |
| Total Assets | $15 million |
| Total Liabilities | $5.5 million |
Future Projections
Analysts forecast that the company may achieve significant growth if its clinical trials yield positive results and lead to marketable products. The potential revenue from approved therapies is projected to reach upwards of $50 million annually within five years.
Immix Biopharma, Inc. (IMMX) Mission Statement
Company Overview
Immix Biopharma, Inc. is a biotechnology company focused on developing innovative cancer therapies. The firm specializes in creating treatments that target cancer cells while improving patient outcomes. The company is publicly traded under the ticker symbol IMMX.
Mission Statement
The mission of Immix Biopharma, Inc. is to transform the treatment landscape for cancer patients through the discovery and development of proprietary biopharmaceuticals. The company aims to deliver effective therapies that improve survival rates and quality of life.
Core Values
- Innovation: Commitment to research and pioneering treatments.
- Integrity: Upholding ethical standards in all business practices.
- Collaboration: Partnering with stakeholders to advance healthcare solutions.
- Patient-Centricity: Prioritizing patient needs in every aspect of development.
Recent Financial Performance
As of the most recent quarterly report for Q3 2023, Immix Biopharma reported the following financial figures:
| Financial Metric | Q3 2023 Amount | Q2 2023 Amount | Q1 2023 Amount |
|---|---|---|---|
| Total Revenue | $1.2 million | $0.8 million | $0.5 million |
| Net Loss | $(5.5) million | $(4.9) million | $(3.7) million |
| Cash and Cash Equivalents | $10 million | $11 million | $12 million |
| R&D Expenses | $4.0 million | $3.5 million | $2.5 million |
Strategic Goals
Immix Biopharma aims to achieve several strategic goals in the upcoming years:
- Advance Clinical Trials: Continue development of lead candidates in clinical phases.
- Partnership Expansion: Seek collaborations with pharmaceutical giants for co-development.
- Regulatory Approvals: Achieve key milestones in obtaining FDA approvals for therapies.
- Market Penetration: Increase product availability in international markets.
Recent Developments
In October 2023, Immix Biopharma announced the initiation of Phase II clinical trials for its lead candidate, IMX-101, targeting solid tumors. This follows encouragement received from the FDA based on positive Phase I results.
Investment Highlights
As of October 2023, the market capitalization of Immix Biopharma stands at approximately $50 million. The company seeks to attract investments by showcasing:
- Innovative pipeline of therapies.
- Strong intellectual property portfolio.
- Experienced management team with a proven track record.
- Growing interest in oncology treatments globally.
How Immix Biopharma, Inc. (IMMX) Works
Company Overview
Immix Biopharma, Inc. (IMMX) focuses on developing innovative therapies for cancer and other serious diseases. The company's primary goal is to address unmet medical needs through its proprietary drug candidates.
Pipeline of Drug Candidates
Immix Biopharma has several potential therapies in its pipeline. The most notable candidates include:
- IMX-101: An investigational product aimed at treating solid tumors.
- IMX-201: Designed for hematological malignancies.
- IMX-301: Targeted toward immune-oncology applications.
Financial Performance
As of Q3 2023, Immix Biopharma reported the following financial figures:
| Financial Metric | Amount (USD) |
|---|---|
| Revenue | $0 |
| Net Loss | $(8.2) million |
| Total Assets | $15.5 million |
| Total Liabilities | $4.1 million |
| Cash and Cash Equivalents | $10.5 million |
Research and Development
R&D expenses remain a significant focus for Immix Biopharma. In the last fiscal year, R&D expenditures were reported at:
| Fiscal Year | R&D Expenditures (USD) |
|---|---|
| 2022 | $5.0 million |
| 2023 (Q3) | $4.0 million |
Market Position and Partnerships
Immix Biopharma is strategically positioned in the biotechnology sector. The company collaborates with various research institutions and participates in partnerships to enhance its development capabilities. Key partnerships include:
- Collaboration with leading cancer research centers.
- Partnerships for clinical trial management.
- Engagement with pharmaceutical companies for co-development opportunities.
Stock Performance
As of October 2023, the stock performance of Immix Biopharma is as follows:
| Stock Metric | Value |
|---|---|
| Current Share Price | $1.25 |
| Market Capitalization | $25 million |
| 52-Week High | $3.00 |
| 52-Week Low | $0.80 |
Future Outlook
Immix Biopharma's future growth will depend on the successful development of its drug candidates and potential market approvals. The anticipated milestones include:
- Phase 1 Clinical Trials for IMX-101 scheduled for Q4 2023.
- Filing for Investigational New Drug (IND) status for IMX-201 by early 2024.
- Expansion of the pipeline with new drug candidates.
How Immix Biopharma, Inc. (IMMX) Makes Money
Revenue Streams
Revenue Streams
Immix Biopharma, Inc. generates revenue primarily through the development and commercialization of innovative therapeutic products aimed at treating cancer and other serious diseases. The company focuses on a diversified portfolio that includes several key programs in various stages of clinical development.
Collaborative Agreements
Immix Biopharma has established strategic partnerships with biotechnology firms and pharmaceutical companies. These collaborations often involve:
- Revenue-sharing agreements
- Joint development programs
- Licensing arrangements
As of the latest financial reports, the company has disclosed revenues of approximately $1.5 million from collaborative agreements in the last fiscal year.
Grants and Funding
The company actively pursues grants from governmental and non-governmental organizations for research and development. In the previous year, Immix secured $750,000 in grant funding to support its clinical trials.
Clinical Trials and Milestones
Immix Biopharma engages in clinical trials for its therapeutic products. The completion of successful phases often results in milestone payments from partners:
| Phase | Milestone Amount |
|---|---|
| Phase 1 | $500,000 |
| Phase 2 | $1 million |
| Phase 3 | $2 million |
These milestone payments are critical to funding ongoing operations and further development of existing and new therapies.
Product Sales
While still in the development phase, any future sales of approved products will create a significant revenue stream for Immix. The potential market for their lead candidates is estimated at several billion dollars annually. Market analysis indicates:
- Total Addressable Market (TAM): $5 billion
- Expected market share within 5 years: 10%
- Projected annual revenue from market share: $500 million
Stock Performance and Investment
As a publicly traded company, Immix Biopharma also raises funds through equity financing. The current stock price is approximately $2.50 per share, with a market capitalization of $50 million as of the latest trading session. The company has raised approximately $10 million in the past 12 months through stock offerings.
Financial Overview
According to the latest quarterly reports, the financial position of Immix Biopharma shows:
| Financial Metric | Amount |
|---|---|
| Total Revenue | $2.25 million |
| Total Expenses | $6 million |
| Net Income/Loss | -$3.75 million |
| Cash Reserves | $8 million |
This financial overview indicates the current state of revenues against the backdrop of operational costs, highlighting the investment needs for future growth.
Market Trends and Projections
The biopharmaceutical market is expected to grow significantly, with estimated annual growth rates of 7.5% over the next five years. This growth can enhance the revenue potential for companies like Immix that are focused on oncology and rare disease therapeutics.
Immix Biopharma, Inc. (IMMX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support